• Co-PSMA abstract accepted for oral presentation at EAU Congress 2026
• Co-PSMA trial demonstrated 64Cu-SAR-bisPSMA detected more lesions than standard-of-care 68Ga-PSMA-11
• 64Cu-SAR-bisPSMA has shown improved diagnostic performance in multiple clinical trials

Clarity Pharmaceuticals (ASX: CU6) announced that an abstract on the Co-PSMA (NCT06907641) Investigator-Initiated Trial, led by Prof Louise Emmett at St Vincent's Hospital Sydney, has been accepted for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026. The Co-PSMA trial evaluated the performance of Clarity's diagnostic product, 64Cu-SAR-bisPSMA, in a head-to-head comparison to standard-of-care (SOC) 68Ga-PSMA-11 in 50 patients with low prostate-specific antigen (PSA) who were candidates for curative salvage therapy. The results to be presented at the EAU Congress 2026 will expand on the earlier findings that the trial met its primary endpoint, demonstrating that 64Cu-SAR-bisPSMA positron emission tomography (PET) / computed tomography (CT) detected significantly more lesions per patient than the SOC, 68Ga-PSMA-11 PET/CT. These results further build on the growing body of evidence showing that 64Cu-SAR-bisPSMA improves the detection of prostate cancer, compared to the current SOC prostate-specific membrane antigen (PSMA) PET agents which are known to have low sensitivity, especially in patients with low PSA levels. Clarity's Executive Chairperson, Dr Alan Taylor, commented that the acceptance of the Co-PSMA data by this world-leading urology conference for an oral presentation is a testament to its strength and quality, and underscores the significant potential of 64Cu-SAR-bisPSMA to advance PSMA imaging and improve prostate cancer management.